SCYNEXIS INC (SCYX) Stock Price & Overview
NASDAQ:SCYX • US8112922005
Current stock price
The current stock price of SCYX is 1.11 USD. Today SCYX is up by 5.71%. In the past month the price increased by 24.16%. In the past year, price increased by 22.75%.
SCYX Key Statistics
- Market Cap
- 49.573M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.18
- Dividend Yield
- N/A
SCYX Stock Performance
SCYX Stock Chart
SCYX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SCYX. When comparing the yearly performance of all stocks, SCYX is one of the better performing stocks in the market, outperforming 87.66% of all stocks.
SCYX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SCYX. While SCYX seems to be doing ok healthwise, there are quite some concerns on its profitability.
SCYX Earnings
On March 4, 2026 SCYX reported an EPS of 0.24 and a revenue of 18.65M. The company beat EPS expectations (87.34% surprise) and beat revenue expectations (125.68% surprise).
SCYX Forecast & Estimates
9 analysts have analysed SCYX and the average price target is 3.54 USD. This implies a price increase of 219.17% is expected in the next year compared to the current price of 1.11.
For the next year, analysts expect an EPS growth of -155.07% and a revenue growth -75.28% for SCYX
SCYX Groups
Sector & Classification
SCYX Financial Highlights
Over the last trailing twelve months SCYX reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS increased by 59.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.58% | ||
| ROE | -17.44% | ||
| Debt/Equity | 0 |
SCYX Ownership
SCYX Latest News, Press Relases and Analysis
SCYX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.51 | 854.108B | ||
| JNJ | JOHNSON & JOHNSON | 18.46 | 564.915B | ||
| MRK | MERCK & CO. INC. | 23.38 | 285.462B | ||
| PFE | PFIZER INC | 9.22 | 154.837B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.5 | 120.381B | ||
| ZTS | ZOETIS INC | 17.3 | 50.25B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.68 | 27.966B | ||
| VTRS | VIATRIS INC | 5.89 | 16.314B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.51 | 11.5B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.421B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.081B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.929B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.07 | 4.676B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SCYX
Company Profile
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 18 full-time employees. The company went IPO on 2014-05-02. The company is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. The company is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
Company Info
IPO: 2014-05-02
SCYNEXIS INC
1 Evertrust Plaza, 13th Floor
Jersey City NEW JERSEY 07302 US
CEO: Marco Taglietti
Employees: 18
Phone: 12018845485
SCYNEXIS INC / SCYX FAQ
Can you describe the business of SCYNEXIS INC?
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 18 full-time employees. The company went IPO on 2014-05-02. The company is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. The company is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
Can you provide the latest stock price for SCYNEXIS INC?
The current stock price of SCYX is 1.11 USD. The price increased by 5.71% in the last trading session.
Does SCYNEXIS INC pay dividends?
SCYX does not pay a dividend.
How is the ChartMill rating for SCYNEXIS INC?
SCYX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about SCYNEXIS INC (SCYX) stock?
9 analysts have analysed SCYX and the average price target is 3.54 USD. This implies a price increase of 219.17% is expected in the next year compared to the current price of 1.11.
Is SCYNEXIS INC (SCYX) expected to grow?
The Revenue of SCYNEXIS INC (SCYX) is expected to decline by -75.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of SCYX stock?
SCYNEXIS INC (SCYX) has a market capitalization of 49.57M USD. This makes SCYX a Nano Cap stock.